Castle Biosciences CSTL 深 滬
等待開盤 03-26 09:30:00 美东时间
25.27
-0.080
-0.32%
華盛通- 最 高26.19
- 今 開25.81
- 成交量 28.09万股
- 最 低 25.08
- 昨 收 25.35
- 總市值 7.51亿
- 52周最高 44.28
- 市盈率 靜 --
- 換手率 0.94%
- 52周最低 14.59
- 委 比 48.45%
- 總股本 2973.12万
- 歷史最高 107.69
- 量 比 1.03
- 振 幅 4.38%
- 歷史最低 9.2601
- 每 手 1
- 風險率 8.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sweden's SciBase Q4 sales rise on US, skin barrier growth
Sweden's SciBase Q4 sales rise on US, skin barrier growth Overview Sweden medical technology firm's Q4 net sales rose 45% yr/yr, loss after tax widened Gross margin fell to 63% from 68.5%, impacted by currency and higher input costs Outlook Company did not provide specific financial or operational g
03-13 15:13
Castle Biosciences' i31‑SLNB Test Validates Predictive Accuracy In Melanoma Study, Supports Safe SLNB Avoidance
Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix.NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (SLNB) if the
03-09 19:12
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Castle Biosciences presented data at the SSO 2026 Annual Meeting showing that their DecisionDx-Melanoma test accurately predicts sentinel lymph node (SLN) positivity in melanoma patients. The i31-SLNB algorithm combines a 31-gene expression profile with clinicopathologic factors to identify low-risk patients with very low SLN positivity rates (2.6% overall, 1.4% in T1b–T2a tumors) and high recurrence-free survival. These findings support the test...
03-09 11:00
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $44
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from $41 to $44.
02-27 20:42
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Exploring Castle Biosciences's Earnings Expectations
Castle Biosciences (NASDAQ:CSTL) is set to give its latest quarterly earnings r...
02-26 04:01
Exploring Castle Biosciences's Earnings Expectations
Castle Biosciences (NASDAQ:CSTL) is set to give its latest quarterly earnings r...
02-26 04:01
Castle Biosciences Publishes A Prospective, Multicenter Clinical Validation Study In The Journal Of The American Academy Of Dermatology Demonstrating That Its AdvanceAD-Tx Test Can Identify Patients With Moderate-To-Severe Atopic Dermatitis Who Are More Likely To Achieve Greater And Faster Clinical Responses When Treated With A Janus Kinase Inhibitor Compared To T Helper Type 2 Targeted Therapies
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter clinical validation study in
02-20 06:51
JAAD study validates Castle Biosciences’ AdvanceAD-Tx test for guiding JAK inhibitor response in atopic dermatitis
JAAD study validates Castle Biosciences’ AdvanceAD-Tx test for guiding JAK inhibitor response in atopic dermatitis Castle Biosciences reported publication in the *Journal of the American Academy of Dermatology* of a prospective, multicenter clinical validation study evaluating its AdvanceAD-Tx gene
02-20 06:46
